Tetramer-binding avidity (KD) of TCR-transduced human T lymphocytes
| KD (KD = −1/slope determined by Scatchard plot) | KD (determined by Tet association and Tet dissociation) | Tet association | Tet dissociation (inhibition with W6/32) | kon calculation | |||
| KD = koff/kon | t1/2 | kob | t1/2 | koff | kon = (kob − koff)/ligand concentration | ||
| nM | nM | Min | min−1 | min | min−1 | nM−1min−1 | |
| CD4+ vα3WT | 73 (slope: −0.014 ± 0.003) | ≥414 | 5.2 (95% CI interval: 2.4 to ∞) | 0.13 ± 0.06 | 2.4 (95% CI interval: 1.1 to ∞) | 0.29 ± 0.13 | ≤0.0007 |
| CD4+ vα3c-90 | 46 (slope: −0.032 ± 0.011) | 100 ± 33 | 5.5 (95% CI interval: 3.2–18.9) | 0.13 ± 0.04 | 10 (95% CI interval: 7.1–17.1) | 0.07 ± 0.01 | 0.0007 ± 0.0001 |
| CD8+ vα3WT | 19 (slope: −0.052 ± 0.003) | 26 ± 7 | 8.1 (95% CI interval: 6.6–11.1) | 0.85 ± 0.01 | 2.7 (95% CI interval: 1.6–9.3) | 0.26 ± 0.07 | 0.01 ± 0.01 |
| CD8+ vα3c-90 | 15 (slope: −0.065 ± 0.008) | 3 ± 1 | 7 (95% CI interval: 4.4–17.9) | 0.99 ± 0.02 | 21.3 (95% CI interval: 12.5–72) | 0.03 ± 0.01 | 0.01 ± 0.01 |
| CD8+ vα13-D3WT | 14 (slope: −0.074 ± 0.026) | 30 ± 3 | 8.3 (95% CI interval: 6.6–11.1) | 0.08 ± 0.01 | 26.5 (95% CI interval: 7.8 to ∞) | 0.03 ± 0.01 | 0.001 ± 0.001 |
| CD8+ vα13-D3c-90 | 12 (slope: −0.083 ± 0.043) | 10 ± 1 | 7.1 (95% CI interval: 4.4–17.9) | 0.1 ± 0.02 | 64 (95% CI interval: 10.8 to ∞) | 0.01 ± 0.01 | 0.001 ± 0.001 |
| CD8+ vα21WT | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| CD8+ vα21c-36 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| KD (KD = −1/slope determined by Scatchard plot) | KD (determined by Tet association and Tet dissociation) | Tet association | Tet dissociation (inhibition with W6/32) | kon calculation | |||
| KD = koff/kon | t1/2 | kob | t1/2 | koff | kon = (kob − koff)/ligand concentration | ||
| nM | nM | Min | min−1 | min | min−1 | nM−1min−1 | |
| CD4+ vα3WT | 73 (slope: −0.014 ± 0.003) | ≥414 | 5.2 (95% CI interval: 2.4 to ∞) | 0.13 ± 0.06 | 2.4 (95% CI interval: 1.1 to ∞) | 0.29 ± 0.13 | ≤0.0007 |
| CD4+ vα3c-90 | 46 (slope: −0.032 ± 0.011) | 100 ± 33 | 5.5 (95% CI interval: 3.2–18.9) | 0.13 ± 0.04 | 10 (95% CI interval: 7.1–17.1) | 0.07 ± 0.01 | 0.0007 ± 0.0001 |
| CD8+ vα3WT | 19 (slope: −0.052 ± 0.003) | 26 ± 7 | 8.1 (95% CI interval: 6.6–11.1) | 0.85 ± 0.01 | 2.7 (95% CI interval: 1.6–9.3) | 0.26 ± 0.07 | 0.01 ± 0.01 |
| CD8+ vα3c-90 | 15 (slope: −0.065 ± 0.008) | 3 ± 1 | 7 (95% CI interval: 4.4–17.9) | 0.99 ± 0.02 | 21.3 (95% CI interval: 12.5–72) | 0.03 ± 0.01 | 0.01 ± 0.01 |
| CD8+ vα13-D3WT | 14 (slope: −0.074 ± 0.026) | 30 ± 3 | 8.3 (95% CI interval: 6.6–11.1) | 0.08 ± 0.01 | 26.5 (95% CI interval: 7.8 to ∞) | 0.03 ± 0.01 | 0.001 ± 0.001 |
| CD8+ vα13-D3c-90 | 12 (slope: −0.083 ± 0.043) | 10 ± 1 | 7.1 (95% CI interval: 4.4–17.9) | 0.1 ± 0.02 | 64 (95% CI interval: 10.8 to ∞) | 0.01 ± 0.01 | 0.001 ± 0.001 |
| CD8+ vα21WT | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| CD8+ vα21c-36 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
n.d., not determined because of the loss of tetramer binding at 37°C as compared with 0°C.